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Abstract
Background: Hypophysitis is an umbrella term for a group of disorders involving inflammation of the pituitary
gland. A rare occurrence in humans, hypophysitis can produce a range of clinical signs including (but not limited
to) visual deficits and diabetes insipidus. Only five cases of canine hypophysitis exist in the literature, all presenting
in mature dogs with no visual deficits and a grave outcome. This case report describes the clinical and advanced
imaging features of blindness-inducing presumptive hypophysitis in a dog, which rapidly resolved with medical
management.
Case presentation: A 1-year-and-seven-month-old neutered male Standard Poodle presented with subacute
blindness, ataxia, and polyuria/polydipsia (PUPD). Magnetic resonance imaging (MRI) detected a contrast-enhancing
pituitary mass with perilesional oedema compromising the optic chiasm. Suspecting neoplasia, anti-inflammatory
corticosteroid was commenced prior to radiation therapy planning. Complete resolution of neurological and visual
deficits occurred within 12 days of starting steroid treatment. Repeated advanced imaging indicated macroscopic
resolution of the lesion. An extended thyroid panel with insulin-like growth factor-1 analysis supported a diagnosis
of hypophysitis. Resolution of PUPD was achieved with tapering courses of prednisolone and desmopressin; the
dog has since been clinically normal for 14 months and treatment-free for 11 months.
Conclusions: To the authors’ knowledge, this is the first instance in which a canine pituitary mass has demonstrated
long-term resolution with palliative medical treatment alone, alongside reversal of associated blindness and presumptive
diabetes insipidus. We suspect this lesion to be a form of hypophysitis, which should be included among differential
diagnoses for pituitary masses, and for subacute blindness in dogs. Where possible, we advocate biopsy-confirmation of
hypophysitis prior to timely intervention with anti-inflammatory treatment.
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Background
Pituitary masses can represent neoplastic, cystic, infec-
tious and/or inflammatory pathology. In dogs, the most
common aetiology is neoplastic; macroadenomas, inva-
sive adenomas and adenocarcinomas tend to present in
mature animals, whilst the less common suprasellar
germ cell tumour presents in younger dogs [1]. Cystic
and inflammatory masses such as Rathke’s cleft cysts
and immune-mediated lymphocytic hypophysitis occur
far less frequently [1]. These lesions are however import-
ant to identify, given their potential to have a radically
different prognosis relative to neoplasia if managed
appropriately [2, 3]. Differentiating each of the above
aetiologies using advanced imaging is problematic, since
they exhibit variable and overlapping radiological features.
For example with MRI, all of these masses can appear
T2-weighted (T2w) hyperintense to normal grey matter,
with variable T1-weighted (T1w) intensity, contrast en-
hancement, and varying degrees of perilesional oedema;
neoplastic lesions can also have secondary cystic or
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haemorrhagic foci [1]. In humans, typical MRI features of
hypophysitis include symmetrical pituitary enlargement,
loss of normal neurohypophyseal T1w hyperintensity,
and homogeneous contrast enhancement [1], however
complete radiological descriptions of canine hypophy-
sitis are lacking [1, 4, 5].
Clinical signs associated with pituitary neoplasms de-
pend on their size and secretory properties; an import-
ant tumour in the dog is the corticotroph adenoma
resulting in hypercortisolism [2]. Non-functional pituit-
ary masses become clinically relevant when their mass
effect induces pituitary dysfunction (leading to a range
of endocrinopathies such as hypothyroidism and central
diabetes insipidus) and/or neurological signs including
changes in mentation, behaviour, or appetite, abnormal
gait, seizures, visual loss and other cranial nerve deficits
[2, 6]. Human hypophysitis is subclassified according to
the structures affected (adenohypophysitis, infundibulo-
neurohypophysitis or pan-hypophysitis), and can be pri-
mary (autoimmune), or secondary to systemic disease, local
lesions or immunomodulatory drugs [7]. Primary hypophy-
sitis is further categorized histopathologically as lympho-
cytic, granulomatous or xanthomatous – however the
pathogenesis of each remains ill-defined [3]. Lymphocytic
and granulomatous hypophysitis typically disrupt adrenal,
gonadal and thyroidal axes, and produce diabetes insipidus
and visual deficits [3]. Only five cases of canine hypophysi-
tis have been reported (Table 1); none of these presented
with visual deficits and all resulted in a grave out-
come [4, 5, 8–11]. The aim of this report is to describe the
successful treatment of presumptive hypophysitis in a dog,
resolving all associated clinical signs including blindness
and suspected diabetes insipidus. Further we provide ad-
vanced imaging details of the mass lesion before treatment
and after apparent macroscopic resolution. Finally we com-
pare and contrast our findings to previously reported cases
in this species as well as humans, and discuss factors that
may contribute to the development of hypophysitis.
Case presentation
A 1-year-and-seven-month-old neutered male Standard
Poodle presented to a primary veterinarian with PUPD,
shivering and mild pyrexia (39.3 °C). Ongoing medica-
tion included oclacitinib maleate1 (0.45 mg/kg orally
every 12 h) for atopic dermatitis. A urine dipstick test
was normal, but after two days without improvement,
amoxicillin-clavulanate2 (15.8 mg/kg orally every 12 h
for 14 days) and meloxicam3 (100 μg/kg orally every
24 h for 5 days) were prescribed. 6 days later, the dog re-
presented with 4-limb ataxia and blindness. He was sub-
dued and remained polydipsic, with a reduced appetite.
Haematology and biochemistry did not yield any clinic-
ally significant data, and an adrenocorticotrophic hor-
mone (ACTH) stimulation test was within normal limits.
At referral, pale mucous membranes and bradycardia
(48 bpm) were noted. Neurological examination revealed
visual loss with absent menace responses bilaterally,
marked bilateral mydriasis and partially responsive
pupillary light reflexes (PLRs). Ophthalmological examin-
ation and electroretinography confirmed normal ocular
anatomy and normal retinal function respectively.
Magnetic resonance imaging (Fig. 1) revealed a T1w isoin-
tense, homogeneously contrast-enhancing, symmetrical,
dumbbell-shaped pituitary mass of 15 mm height (pituit-
ary height/brain area [P/B] ratio of 0.85 [12]), with moder-
ately increased perilesional signal on T2w images that did
not suppress on fluid-attenuated inversion recovery
(FLAIR). The lesion was also isointense on T2*, and to-
gether with the oedema exerted a mass effect on the optic
chiasm. Cisternal cerebrospinal fluid (CSF) analysis
yielded a lymphocytic pleocytosis (total nucleated cell
count 34 per μl with 85% lymphocytes; protein
Table 1 Reported cases of hypophysitis in the dog
Signalment Presentation Treatment Outcome Diagnosis Reference
9 y MN Samoyed 3 y dermatitis and blepharitis Medical therapy Euthanasia Lymphoplasmacytic adenohypophysitis
and sebaceous adenitis
[10]
4.5 y FE Great
Pyrenees
2 m progressive paresis and
pelvic limb muscle atrophy
Prednisolone
Levothyroxine
Euthanasia Lymphocytic adenohypophysitis and
adrenalitis with polyendocrine syndromea
[8]
10 y FE
Crossbreed
3 m progressive anorexia and
weight loss; gastroenteritis,
pyrexia
IVFT
Ranitidine
Fenbendazole
Sudden death Lymphoplasmacytic adenohypophysitis
with adrenal insufficiency and giardiasis
[11]
8 y ME German
Longhaired
Pointer
Acute onset PUPD, exercise
intolerance, dull mentation
and hair coat
Desmopressin
Hypophysectomy
Mannitol
Euthanasia Lymphocytic hypophysitis with central
diabetes insipidus
[5]
6 y MN
Scottish Terrier
One week progressive lethargy,
anorexia, pelvic limb ataxia
Not reported Death after acute
severe hypernatraemia
Lymphocytic panhypophysitis with
extension to hypothalamus and
polyendocrine syndromeb
[4]
ahypothyroidism and hypoadrenocorticism; bsuspected primary hypoadrenocorticism and secondary hypothyroidism; PUPD polyuria/polydipsia, IVFT intravenous
fluid therapy, MN neutered male, FN neutered female, ME intact male, FE intact female. Note that the sellar xanthogranuloma with polyendocrine syndrome in a 7
year-old neutered male Standard Poodle reported by Cramer et al. [9] is not included in the table due to current controversy regarding the classification of this as
a separate entity from hypophysitis, based on pathogenesis
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concentration 49 mg/dL) which, alongside MRI findings,
suggested a neoplastic, immune-mediated or infectious
process. The most likely differential in a dog was pituitary
neoplasia.
The owner elected for medical management and radi-
ation therapy. Three days after commencing prednisol-
one4 (0.91 mg/kg orally every 24 h), PLRs were intact,
and the visual function and gait were improving. Poly-
dipsia however persisted, and urinalysis showed an in-
active sediment with urine specific gravity (USG) of
1.010. Partial central diabetes insipidus and/or the influ-
ence of prednisolone treatment were considered as po-
tential contributing factors. After a further 9 days, the
neurological signs had abated; the dog was completely
visual but expressed marked PUPD. Vasopressin
analogue, desmopressin5 was commenced at 10 μg/kg
(4 drops in each eye every 12 h). The dog was trans-
ferred a week later to a second referral hospital for
radiation therapy planning. The PUPD had improved,
but there was generalized muscle atrophy and weight
loss (of 1.8 kg), with a body condition score of 3/9.
Neurologically the dog was normal. Repeated haema-
tology and biochemistry revealed increased cholesterol
(321 mg/dL; reference range 147–271 mg/dL) and a
few reactive lymphocytes. Urinalysis confirmed iso-
sthenuria (USG 1.009). Computed tomography of the
head and thorax detected no evidence of metastatic
disease and the pituitary gland was normal in size,
suggesting resolution of an inflammatory lesion.
Two days later the owner reported further improve-
ment with prednisolone and desmopressin; oclacitinib
maleate was being given at maintenance frequency (once
daily). Repeated MRI (Fig. 2) indicated complete macro-
scopic resolution of the mass (pituitary height had re-
duced from 15 mm to 4 mm with a P/B ratio of 0.23)
and was considered to be within normal limits [1, 12]),
with no apparent residual oedema or compression of
surrounding tissues. We were not aware of any literature
reporting such a dramatic response of a canine pituitary
neoplasm to palliative medical treatment alone [2]. On
this basis, the differentials included primary hypophysi-
tis, iatrogenically-induced hypophysitis [7], hypophysitis
secondary to a ruptured cyst of Rathke’s pouch [1, 13] or
an infection [1, 10], and sellar xanthogranuloma [9].
Serology for Toxoplasma and Neospora was negative,
whilst endocrine serology (Table 2) was consistent with
hyposomatotropism, which can occur secondarily to
hypophysitis [5]. Given the possibility of an immune-
mediated aetiology, oclacitinib maleate was curtailed and
prednisolone was tapered over 10 weeks. Two weeks
later the dog had gained weight; after a further 4 weeks
his urine was hypersthenuric and the PUPD had re-
solved. Desmopressin was tapered over 5 weeks. During
a 14-month follow-up, there has been no recrudescence
Fig. 1 Transverse T2w, T1w, FLAIR and T1w post-contrast (a, b, c, d) and sagittal T1w post-contrast (e) magnetic resonance images through the
pituitary fossa. Note, in all sequences, the enlarged pituitary gland (white arrow) with associated perilesional brain oedema (black arrow) in the
FLAIR image (c). Note the avid contrast enhancement of the enlarged pituitary gland on T1w transverse and sagittal post-contrast images (d, e).
Images were acquired with a 1.5 T Magneton Essenza MRI scanner
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of the clinical signs and the dog has been without treat-
ment for 11 months.
Discussion
The rapid emergence of subdued behaviour, reduced ap-
petite, and blindness described above resemble common
symptoms of hypophysitis in humans including head-
ache and visual disturbances [3]. These signs are also
consistent with a histpathologically-confirmed case of
lymphocytic panhypophysitis in a Scottish Terrier [4];
visual dysfunction was not reported in that dog, which
could be due to a more dorsal (rather than rostral) ex-
tension of the lesion relative to our case [4]. By contrast,
canine pituitary neoplasms tend to present more insidi-
ously, and visual dysfunction would likely only be seen
as a late-emerging sign in the few cases that had gone
untreated, or non-functional tumours that had remained
clinically silent for a prolonged period [2]. Occasionally,
pituitary apoplexy can present secondary to acute haem-
orrhage within a neoplastic lesion [14], but the lack of
T2* signal void in our case makes haemorrhage highly
unlikely. Magnetic resonance is the preferred imaging
modality for hypophysitis in humans, but has only been
described for two dogs, both of which had inflammatory
extension to other parts of the brain [1, 4]. The isointen-
sity of the canine mass on T1w images, together with
marked contrast enhancement and lack of cystic changes
is consistent with a lymphocytic or granulomatous sub-
type [3]. The shape, hyperintensity on T2w sequences,
and lack of T2* signal void are additional features of this
lesion which match those described by Oliveira et al. [4].
By contrast both to our report and the human literature,
the authors refer to a hypointensity (rather than a loss of
normal pituitary hyperintensity) on pre-contrast T1w
images [1, 4]. As expected due to its rich vascular sup-
ply, the normal post-treatment pituitary gland in our
Standard Poodle remained markedly contrast-enhancing
relative to brain tissue, with a focal T1 hyperintensity
and isointensity to cortical grey matter on T2w sequences
Table 2 Endocrinology panela
Analyte Value Unit Reference range
Thyroxine (T4) by RIAb 16.6 nmol/l 13–52
Free T4 equilibrium
dialysis (RIAb)
7.1 pmol/l 7–40
TSH by IRMAc 0.23 ng/ml <0.41
Thyroid antiglobulin
antibody
52 % <200
IGF-1 47 ng/ml >200 adults of large
breeds
>500 puppies
<50 dwarfism
>1000 acromegaly
a(NationWide Specialist Laboratories, Cambridge; Canine Platinum Thyroid Profile
and IGF-1); bradioimmunoassay; cimmunoradiometric assay. Note low IGF-1 and
borderline low free T4, with normal total T4, TSH and thyroid antiglobulin antibody.
TSH thyroid stimulating hormone, IGF-1 insulin-like growth factor-1
Fig. 2 Transverse T2w, T1w, FLAIR and T1w post-contrast (a, b, c, d) and sagittal T1w post-contrast (e) magnetic resonance images through the
pituitary fossa. Note, in all sequences, the normal appearance of the pituitary gland in the pituitary fossa; pituitary height was 4 mm. Note the contrast
enhancement of the normal pituitary gland (white arrow) on T1w sagittal post contrast image (e). Images were acquired with a 1.5 T Philips Burgess
Diagnostic MRI scanner
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(Fig. 2) [1]. Alongside the CSF results, our case is there-
fore most consistent with a lymphocytic pan-hypophy-
sitis [3, 5, 9] – although confirmation of hypophysitis
and its subclassification would require histopathology.
In humans, a diagnosis of primary hypophysitis is
often based on relevant symptoms together with MRI
findings because surgery is not needed for resolution [7].
Since the dog’s clinical signs and imaging abnormalities
responded so dramatically to medical management, an
invasive biopsy could not be justified. Likewise, trans-
sphenoidal hypophysectomy can be complicated for
these lesions [5] and the large P/B ratio of the mass
would have increased the risk of post-operative mor-
tality for hypophysectomy [15]. Although bacterial
and canine distemper virus infections were not completely
excluded, the authors consider these to be extremely
unlikely given the nature and course of clinical signs
in this dog.
Adissu et al. [8] likened their hypophysitis case to
‘Schmidt’s syndrome’ – a human condition comprising 2
out of 3 of the major endocrine disorders (hypoadreno-
corticism, hypothyroidism and type I diabetes mellitus),
and recently described in a Dobermann Pinscher [16].
Polyendocrinopathy was not confirmed in our Standard
Poodle, but extended endocrine serology was performed
after corticosteroid treatment had commenced, which
may have impacted upon endocrine axes, and thus
serum levels of the parameters tested. Despite this, the
free T4 was borderline low (Table 2) and overall, the thy-
roid profile was almost identical to that of a Great Pyren-
ees with lymphocytic adenohypophysitis and confirmed
polyendocrinopathy [8]. If treatment had been delayed
further in our case, it is possible that hypothyroidism may
have emerged as part of the clinical picture, or at least
serologically. Our IGF-1 and free T4 results are also con-
sistent with another histopathologically-confirmed ex-
ample of canine lymphocytic hypophysitis [5]. Although
prednisolone may have altered the thyroid profile, it
should not affect serum IGF-1 in the dog [17]. Clinically
therefore, our case is most similar to the Pointer with
lymphocytic hypophysitis, in which hypothyroidism and
hyposomatotropism occurred secondarily to hypopituitar-
ism, and diabetes insipidus responded to desmopressin
[5]. The delayed resolution of PUPD in our Standard
Poodle might have resulted from pituitary stalk damage or
prednisolone treatment. Absence of visual deficits in the
Pointer could be attributed to a slightly smaller P/B ratio
of the pituitary mass (0.75 measured on CT images) [5],
which in our case was large enough to compress the optic
chiasm and potentially also impinge on the optic tracts.
The contrasting outcome between these two cases may re-
flect a combination of prompt administration of cortico-
steroid (rather than surgical debulking [5]), and the young
age of our dog. Irrespectively, it is important to emphasise
that without histopathological confirmation, our diagnosis
of hypophysitis remains presumptive.
Treatment for human hypophysitis has included
debulking, glucocorticoids, azathioprine, methotrexate
and radiation therapy [3]. Corticosteroid is recom-
mended initially for lymphocytic or granulomatous
forms where vision is not at risk, but steroid can fail to
produce long-term resolution [3]. Pre- or post-surgical
glucocorticoid reduced pituitary size in 75% of patients
with the lymphocytic form of hypophysitis, but was less
effective in other subtypes [3]. Neoplasia is not excluded
by mass size reduction and resolution of visual deficits,
which can be achieved medically in patients with aggres-
sive pituitary adenomas [18]. Functional pituitary aden-
oma was however ruled out in this dog by the combined
results of endocrinological testing [5], the extent of
radiological change, and the clinical improvement fol-
lowing medical management alone [2]. Radiation therapy
is typically recommended for canine pituitary neoplasms,
but there is little evidence that it can reverse any visual
dysfunction associated with these [2, 6]. For dogs that
receive no therapy or only symptomatic treatment
(which may include corticosteroid), median survival time
for pituitary neoplasia ranges from 6 days to 359 days [2,
19], and our patient is clinically normal beyond 400 days.
One potential caveat is lymphoma, which can affect the
pituitary [20] and can respond dramatically to cortico-
steroid (started at immunosuppressive doses) [21]. How-
ever, radiological features of primary pituitary lymphoma
are quite distinct from our observations [22, 23] and
canine lymphoma would generally be expected to pro-
gress within 11 months in the absence of specific treat-
ment [2]. There is currently insufficient data to
comment on the anticipated response and survival time
when canine central nervous system lymphoma is
treated with prednisolone as a single agent [19].
Reported cases of canine hypophysitis have ubiqui-
tously resulted in death or euthanasia [4, 5, 8–11]. This
does not necessarily imply a poor prognosis; in the past,
histological confirmation could be achieved only at nec-
ropsy [4, 8, 10, 11]. Although surgical biopsies of pituit-
ary masses have been introduced in veterinary medicine
[24], they are rarely performed due to financial and tech-
nical limitations – the one reported attempt at hypophy-
sectomy specifically for canine hypophysitis resulted in
peri-operative euthanasia [5]. In most of the cases listed
in Table 1, anti-inflammatory treatment was not
attempted based on the suspicion of a neoplastic
process. Prednisolone was administered to one dog, but
not until 2 months after the onset of clinical signs [8].
We cannot presume that every hypophysitis case would
be steroid-responsive; ideally surgical biopsy should be
recommended prior to considering treatment options
for pituitary masses. However where biopsy is not
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possible (and/or consent is withheld), it may be prudent
to institute corticosteroid as soon as hypophysitis is sus-
pected, especially in otherwise healthy dogs.
Relative to previous cases, our Poodle was remarkably
young; we consider therefore that some trigger may have
predisposed him to this condition prematurely. Notably,
oclacitinib maleate treatment commenced prior to the
onset of signs, and twice-daily dosing continued beyond
the recommended loading period [25]. We have no evi-
dence that oclacitinib maleate acts as an inciting or per-
missive factor for this disorder. We would however
caution against the use of janus kinase inhibitors where
potentially life-threatening immune-mediated conditions
are suspected, and where these have developed alongside
treatment. Iatrogenically-induced hypophysitis is recog-
nised in human patients treated with ipilimumab [26],
sitting within a spectrum of endocrinological side effects
of immune checkpoint inhibitors and tyrosine kinase in-
hibitors [27, 28]. In most instances, this can be managed
with glucocorticoids and hormone replacement therapy
[29]. Interestingly, polydipsia, anorexia, lethargy and in-
creased serum cholesterol were reported side effects in
early field trials of oclacitinib maleate in the dog [25].
However, features that make iatrogenically-induced
hypophysitis less likely in this case include a marked
(rather than a moderate) pituitary enlargement, visual
loss, and suspected diabetes insipidus [7].
Genetic diversity of the Standard Poodle is unevenly
distributed across the dog leukocyte antigen (DLA) class
I and II regions, such that the most inbred dogs are
more susceptible to complex autoimmune diseases [30].
Among these, sebaceous adenitis and hypoadrenocorti-
cism have presented alongside hypophysitis in other
breeds [8, 10]. One suggested mechanism is that an aber-
rant immune response targets a unique surface antigen
shared by cells of the adenohypophysis and sebaceous
glands [10], however this remains untested. Cramer et al.
[9] reported sellar xanthogranuloma in a Standard Poodle
which also had mild hypercholesterolaemia, a low free T4,
and behavioural changes [9]. However, by contrast to the
case reported here, the presentation included a year of
premonitory PUPD and cystic cavities within the mass [9].
Overall, the combination of atopy, thyroxine dysregula-
tion, hyposomatotropism and hypophysitis in a Standard
Poodle raises suspicion of an immune-mediated syndrome
linked to the DLA region [30]. This is of interest from a
classification perspective, since the co-existence of other
autoimmune disorders in humans tends to occur only
with the lymphocytic form of hypophysitis [3].
Conclusions
In conclusion, we describe a presumptive case of hypo-
physitis in a dog with associated blindness, hyposomato-
tropism and suspected central diabetes insipidus. All
clinical signs and radiological findings resolved after
treatment with corticosteroids and the dog remains clin-
ically normal 14 months following diagnosis, and
11 months following discontinuation of all treatments.
Features that distinguish this case from previously
reported instances of canine hypophysitis include a
relatively young age at presentation, and long-term reso-
lution in response to early medical management.
Although visual deficits are noted frequently in human
hypophysitis and sometimes with other canine pituitary
masses [2, 3, 6], this is the first report of presumptive
hypophysitis-induced blindness in the dog. MRI features
of hypophysitis have been reported sporadically in canines
[1, 4] and are similar to those described here. However,
these radiological features are not specific for the disorder
and cannot exclude other more common canine pituitary
mass lesions. For this reason, the authors cautiously
favour biopsy-confirmation of hypophysitis followed by
anti-inflammatory corticosteroid and/or radiation therapy
if available. Where biopsy is contraindicated, or where se-
vere clinical signs demand urgent management, gluco-
corticoid might be considered. Though rare, hypophysitis
should be included as a differential for pituitary lesions in
dogs, including those presenting with visual loss.
Endnotes
1Apoquel, Zoetis UK Limited, Surrey, UK.
2Clavaseptin, Vetoquinol, Buckingham, UK.
3Metacam 1.5 mg/ml oral suspension for dogs,
Boehringer Ingelheim Limited, Berkshire, UK.
4Prednidale, Dechra Veterinary Products.
5DDAVP 100 μg/ml solution.
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